Gritstone bio develops personalized and off-the-shelf immunotherapies for cancer and infectious diseases using its EDGE™ platform, which employs artificial intelligence to identify tumor-specific neoantigens. By harnessing the immune system's T cell response, Gritstone aims to enhance the recognition and destruction of cancerous and virally infected cells, improving treatment outcomes for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer and infectious diseases pose significant challenges due to the ability of cancerous and virally infected cells to evade detection and destruction by the immune system. Traditional treatment approaches may not always effectively stimulate a robust and durable T cell response against these abnormal cells, leading to suboptimal outcomes.
Solution
Gritstone bio develops personalized and off-the-shelf immunotherapies designed to enhance the immune system's ability to recognize and eliminate cancerous and virally infected cells. The company's EDGE™ platform employs artificial intelligence to identify tumor-specific neoantigens, which serve as targets for T cell mediated tumor death. By leveraging unique delivery systems, Gritstone aims to stimulate the immune system and drive the generation of T cells and neutralizing antibodies against selected targets. This approach seeks to activate and direct the immune system in a way that extends the benefits of immunotherapy to a broader range of patients.
Target Audience
The primary target audience includes cancer patients, individuals at risk of infectious diseases, and healthcare providers seeking innovative immunotherapeutic solutions.
Features
- EDGE™ AI platform for accurate identification of T cell targets
- Personalized immunotherapy program (GRANITE) targeting patient-specific neoantigens
- Off-the-shelf immunotherapy program (SLATE) targeting shared neoantigens from driver mutations
- Vaccine-based immunotherapy for potential curative treatment of HIV infection
- Next-generation vaccines designed to drive more potent and durable responses against SARS-CoV-2 and other common viral diseases
- Manufacturing capabilities with multiple clean rooms, quality control and assurance, and development labs
- GMP sequencing lab, immune monitoring, and mass spec immunopeptidomics capabilities